Concepedia

Author

Makio Gamoh

Osaki Citizen Hospital

Also Known As

Gamoh Makio, M Gamoh, M. Gamoh, MAKIO GAMOH, Makio GAMOH, Makio Gamoh

83

Publications

759

Citations

14

H-Index

19

Concepts

All Affiliations

Osaki Citizen HospitalTohoku UniversityTohoku University HospitalNational Cancer Center Hospital EastKanagawa Cancer Center
MG

About

Makio Gamoh is an author at Osaki Citizen Hospital specializing in oncology, medicine, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

70

2

Pathology

3

3

59

3

Gastroenterology

2

2

25

4

Health Sciences

1

1

14

5

Immunology

1

1

14

Makio Gamoh

×

21

Publications

672

Citations

14

H-Index

YearCitations

Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1)

Yukinori Kurokawa, Naotoshi Sugimoto, Hiroto Miwa,

British Journal of Cancer

2014

138

Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer

Takayuki Yoshino, Takeharu Yamanaka, Eiji Oki,

JAMA Oncology

2019

96

S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial

Yasuhide Yamada, Tadamichi Denda, Makio Gamoh,

Annals of Oncology

2017

86

Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial

Kentaro Yamazaki, Takeharu Yamanaka, Manabu Shiozawa,

Annals of Oncology

2020

50

Incidence of opioid‐induced constipation in Japanese patients with cancer pain: A prospective observational cohort study

Akihiro Tokoro, Hisao Imai, Soichi Fumita,

Cancer Medicine

2019

42

Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer

Hiroshi Soeda, Hideki Shimodaira, Mika Watanabe,

International Journal of Clinical Oncology

2012

35

Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer

Masahito Kotaka, Takeharu Yamanaka, Takayuki Yoshino,

ESMO Open

2018

28

A New Combination Chemotherapy with Cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for Advanced Esophageal Cancers.

Takashi Yoshioka, Makio Gamoh, Ryusaburo SHINEHA,

Internal Medicine

1999

24

Phase II Trial of Cetuximab plus Irinotecan for Oxaliplatin- and Irinotecan-Based Chemotherapy-Refractory Patients with Advanced and/or Metastatic Colorectal Cancer: Evaluation of Efficacy and Safety Based on <b><i>KRAS</i></b> Mutation Status (T-CORE0801)

Hiroshi Soeda, Hideki Shimodaira, Makio Gamoh,

Oncology

2014

20

Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer

Takashi Yoshioka, Shunsuke Kato, Makio Gamoh,

British Journal of Cancer

2009

20

Page 1